Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 296, Issue 4, 2009, Pages

  Riedel, Michael J ^a   Lee, Corinna Wai Kwan ^a   Kieffer, Timothy J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diabetes; Gene therapy; Liver

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; LUCIFERASE; PYRUVATE KINASE;

ANIMAL CELL; ARTICLE; BIOENGINEERING; ENZYME ASSAY; GENE THERAPY; GLUCOSE BLOOD LEVEL; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; ADENOVIRUS; ANIMAL; ANIMAL DISEASE; BIOASSAY; BLOOD; CELL LINE; CYTOLOGY; DOWN REGULATION; DRUG EFFECT; EVALUATION; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENETICS; HUMAN; MALE; METABOLISM; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; TRANSPLANTATION;

ADENOVIRIDAE; ANIMALS; BIOLOGICAL ASSAY; BLOOD GLUCOSE; CELL LINE; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; GENETIC ENGINEERING; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HEPATOCYTES; HUMANS; MALE; MICE; TRANSDUCTION, GENETIC;

EID: 65649090639     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90768.2008     Document Type: Article

References (39)

1. Bergot MO, Diaz-Guerra MJ, Puzenat N, Raymondjean M, Kahn A. Cis-regulation of the L-type pyruvate kinase gene promoter by glucose, insulin and cyclic AMP. Nucleic Acids Res 20: 1871-1877, 1992.
2. Cha JY, Kim HI, Im SS, Li TZ, Ahn YH. HNF1 and/or HNF3 may contribute to the tissue specific expression of glucokinase gene. Exp Mol Med 33: 59-63, 2001.
3. Cheung AT, Kieffer TJ. Gene therapy for metabolic disease. In: Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, PA: Lippincott Williams and Wilkins, 2004, p. 457-467.
4. Cuif MH, Cognet M, Boquet D, Tremp G, Kahn A, Vaulont S. Elements responsible for hormonal control and tissue specificity of L-type pyruvate kinase gene expression in transgenic mice. Mol Cell Biol 12: 4852-4861, 1992.
5. Davidson MB, Bate G, Kirkpatrick Exenatide P. Nat Rev Drug Discov 4: 713-714, 2005.
6. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957, 1995.
7. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41: 271-278, 1998. (Pubitemid 28254820)
8. Doiron B, Cuif MH, Kahn A, Diaz-Guerra MJ. Respective roles of glucose, fructose, and insulin in the regulation of the liver-specific pyruvate kinase gene promoter. J Biol Chem 269: 10213-10216, 1994. (Pubitemid 24198208)
9. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84: 3434-3438, 1987. (Pubitemid 17085418)
10. Ishiyama T, Kano J, Minami Y, Iijima T, Morishita Y, Noguchi M. Expression of HNFs and C/EBP alpha is correlated with immunocytochemical differentiation of cell lines derived from human hepatocellular carcinomas, hepatoblastomas and immortalized hepatocytes. Cancer Sci 94: 757-763, 2003. (Pubitemid 37258772)
11. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 20: 876-913, 1999.
12. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596, 1995.
13. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52: 751-759, 2003. (Pubitemid 36323583)
14. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H, Wilken M, Agerso H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43: 1664-1669, 2000. (Pubitemid 30304999)
15. Kumar M, Hunag Y, Glinka Y, Prud'homme GJ, Wang Q. Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Gene Ther 14: 162-172, 2007. (Pubitemid 46043821)
16. Lan MS, Wang HW, Chong J, Breslin MB. Coupling of glucose response element from L-type pyruvate kinase and G6Pase promoter enhances glucose responsive activity in hepatoma cells. Mol Cell Biochem 300: 191-196, 2007. (Pubitemid 46881829)
17. Lee YS, Shin S, Shigihara T, Hahm E, Liu MJ, Han J, Yoon JW, Jun HS. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes 56: 1671-1679, 2007. (Pubitemid 46842602)
18. Levrat F, Vallet V, Berbar T, Miquerol L, Kahn A, Antoine B. Influence of the content in transcription factors on the phenotype of mouse hepatocyte-like cell lines (mhAT). Exp Cell Res 209: 307-316, 1993. (Pubitemid 24005316)
19. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88: 2719-2725, 2003. (Pubitemid 36733545)
20. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 21: 91-117, 2005.
21. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835, 1993. (Pubitemid 23188160)
22. Miquerol L, Lopez S, Cartier N, Tulliez M, Raymondjean M, Kahn A. Expression of the L-type pyruvate kinase gene and the hepatocyte nuclear factor 4 transcription factor in exocrine and endocrine pancreas. J Biol Chem 269: 8944-8951, 1994. (Pubitemid 24209210)
23. Mitanchez D, Doiron B, Chen R, Kahn A. Glucose-stimulated genes and prospects of gene therapy for type I diabetes. Endocr Rev 18: 520-540, 1997. (Pubitemid 27349555)
24. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307, 1993. (Pubitemid 23037285)
25. Nguyen TH, Ferry N. Liver gene therapy: advances and hurdles. Gene Ther 11, Suppl 1: S76-S84, 2004.
26. Oh S, Lee M, Ko KS, Choi S, Kim SW. GLP-1 gene delivery for the treatment of type 2 diabetes. Mol Ther 7: 478-483, 2003. (Pubitemid 36553416)
27. Parsons GB, Souza DW, Wu H, Yu D, Wadsworth SG, Gregory RJ, Armentano D. Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes. Gene Ther 14: 38-48, 2007.
28. Plamboeck A, Holst JJ, Carr RD, Deacon Neutral endopeptidase 24 CF.11. and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48: 1882-1890, 2005. (Pubitemid 41317844)
29. Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-211, 1997. (Pubitemid 27060294)
30. Rencurel F, Girard J. Regulation of liver gene expression by glucose. Proc Nutr Soc 57: 265-275, 1998. (Pubitemid 128737053)
31. Satoh S, Noaki T, Ishigure T, Osada S, Imagawa M, Miura N, Yamada K, Noguchi T. Nuclear factor 1 family members interact with hepatocyte nuclear factor 1alpha to synergistically activate L-type pyruvate kinase gene transcription. J Biol Chem 280: 39827-39834, 2005. (Pubitemid 41779116)
32. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 16: 270-276, 1997. (Pubitemid 27280211)
33. Soltani N, Kumar M, Glinka Y, Prud'homme GJ, Wang Q. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther 14: 981-988, 2007. (Pubitemid 46865509)
34. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86: 3717-3723, 2001. (Pubitemid 32755966)
35. Vaulont S, Munnich A, Decaux JF, Kahn A. Transcriptional and post-transcriptional regulation of L-type pyruvate kinase gene expression in rat liver. J Biol Chem 261: 7621-7625, 1986. (Pubitemid 17208678)
36. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50: 609-613, 2001. (Pubitemid 32195226)
37. Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, Boyd AE, III. Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 133: 57-62, 1993. (Pubitemid 23206374)
38. Xiao Q, Giguere J, Parisien M, Jeng W, St Pierre SA, Brubaker PL, Wheeler MB. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40: 2860-2869, 2001. (Pubitemid 32198288)
39. Zhang J, Tokui Y, Yamagata K, Kozawa J, Sayama K, Iwahashi H, Okita K, Miuchi M, Konya H, Hamaguchi T, Namba M, Shimomura I, Miyagawa JI. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 50: 1900-1909, 2007. (Pubitemid 47222856)